Research and Studies
Our Research Department
Houston Eye Associates has been conducting research since 1976. We conduct studies used in the treatment of glaucoma, cataracts, conjunctivitis, strabismus, uveitis, retina, and other eye diseases.
We have highly qualified and educated staff who are Certified Phlebotomists, Clinical Research Coordinators, Recruiters, and Research Assistants. Our research department uses state-of-the-art equipment and fully equipped eye exam rooms.
If you are interested in participating in one of our studies, please call 832-553-7100.
Newsletter Signup
NCX-470-02: Mont Blanc
A Phase 3, Randomized, Adaptive Dose-Selection, Multi-Regional, Double-Masked, Parallel-Group, 3-Month Trial Evaluating the Safety and Efficacy of NCX 470 vs. Latanoprost 0.005% in Subjects with Open-Angle Glaucoma or Ocular Hypertension (Mont Blanc)
NCX-470-03: Denali
A Phase 3, Randomized, Multi-Regional, Double-Masked, Parallel-Group Trial Evaluating the Safety and Efficacy of NCX 470 0.1% vs. Latanoprost 0.005% in Subjects with Open-Angle Glaucoma or Ocular Hypertension (Denali)
BTQ-1901-1902-201: Betaliq
A Randomized, Multicenter, Observer-Masked Study to Compare the Safety and Efficacy of BTQ-1901-A, BTQ-1901-B, and BTQ-1902 to Timolol 0.5% in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension
C-100-001: Surface
A multicenter, randomized, double-masked study to evaluate the safety, tolerability, and efficacy of surf-100 ophthalmic solution (a mycophenolic acid/betamethasone sodium phosphate combination) in subjects with dry eye disease.
CPN-302: Formosa-AimMax
A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study
to Evaluate the Efficacy and Safety of APP13007 for the Treatment of Inflammation and
Pain after Cataract Surgery, Including a Corneal Endothelial Cell Sub-study.
Aerie | AR-13324-CS210
A Randomized, Open-Label, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Dosing Regimens of Netarsudil Ophthalmic Solution in Patients with Corneal Edema Due to Fuchs Corneal Dystrophy
Novartis | CSAF312B12201: SAF312
A 12-week parallel group, randomized, placebo-controlled, double-blinded, multi-center study to evaluate efficacy and safety of 2 concentrations of SAF312 eye drops (5 mg/ml and 15 mg/ml) used twice-daily in the treatment of post-operative corneal induced chronic pain (CICP) following Photorefractive Keratectomy (PRK) or Laser-assisted in Situ Keratomileusis (LASIK) surgeries
Recordati | REC0559-B-001
Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients
Alcon | ILR431B-P001
Post Approval Study of the AcrySof® IQ ReSTOR® Toric IOLs
Biorasi CLR_16_33
A Randomized, Multi-Center, Investigator-Masked, Parallel Group,
Equivalence Study of Once Daily Brimonidine Tartrate Ophthalmic
Suspension Compared with Three Times Daily Alphagan® P in Subjectswith Open Angle Glaucoma or Ocular Hypertension.
See the difference at Houston Eye Associates!
